electroCore Appoints Multiple Industry Veterans to Key Management Positions
“I would like to thank Peter and Glenn for their dedication and contributions to the company as we worked through
Dr. Fiorino will oversee the ongoing clinical development of the company’s gammaCore™ non-invasive vagus nerve stimulator into new potential indications, including migraine prevention and diseases of inflammation, such as rheumatoid arthritis. Mr. Posner will lead the financial planning, financial management and investor relations functions.
“Tony and Brian are both highly accomplished healthcare executives, and I look forward to their contributions as we continue executing on our gammaCore commercial growth plan,” said Mr. Amato. “I believe we have established a leadership team that will shepherd the company through its next phase of growth.”
“I joined electroCore because I am excited by the potential of the company’s vagus nerve stimulation technology,” commented Dr. Fiorino. “I look forward to working with the team to accelerate the company’s clinical development plans and make this technology available to patients globally.”
“I am pleased to join the electroCore team at this pivotal time in the commercial roll-out and ongoing development of gammaCore,” said Mr. Posner. “The market opportunity for this technology is significant, and I believe the achievement of anticipated commercial and development milestones can yield significant shareholder value.”
Dr. Fiorino joins electroCore from Immune Pharma, where he served as interim chief executive officer since
Mr. Posner joins electroCore from
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and product development plans, its pipeline or potential markets for its technologies, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the
LifeSci Public Relations